Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The overall goal of this proposal is to determine the effectiveness and safety of once weekly
alendronate (Fosamax) in the prevention and treatment of osteoporosis in men with prostate
cancer on androgen deprivation therapy and to evaluate maintenance of bone mass following
termination of therapy after one year.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)